MyFinsight
Home
Blog
About
Cash and cash
equivalents
$165,896K
(291.94%↑ Y/Y)
Short-term marketable
securities
$74,232K
(-10.65%↓ Y/Y)
Prepaid expenses and
other current assets
$3,860K
(115.76%↑ Y/Y)
Total current assets
$243,988K
(91.82%↑ Y/Y)
Long term marketable
securities
$17,436K
(73.34%↑ Y/Y)
Operating lease
right-of-use assets
$1,951K
(1183.55%↑ Y/Y)
Other assets
$55K
Total assets
$263,430K
(91.72%↑ Y/Y)
Total liabilities and
stockholders' equity
$263,430K
(91.72%↑ Y/Y)
Total stockholders'
equity
$256,155K
(96.80%↑ Y/Y)
Liabilities, total
$7,275K
Accumulated deficit
-$370,952K
(-14.54%↓ Y/Y)
Accumulated other
comprehensive (loss) income
-$77K
(-201.32%↓ Y/Y)
Additional paid-in capital
$627,178K
(38.16%↑ Y/Y)
Total current
liabilities
$5,419K
(-25.22%↓ Y/Y)
Operating lease
liabilities, long-term
$1,856K
Common stock-Common
Class A
$6K
(100.00%↑ Y/Y)
Accrued expenses and
other current...
$4,204K
(-18.75%↓ Y/Y)
Accounts payable
$1,131K
(-41.12%↓ Y/Y)
Operating lease
liabilities
$84K
(-44.74%↓ Y/Y)
Back
Back
Balance Sheet
Sagimet Biosciences Inc. (SGMT)
Sagimet Biosciences Inc. (SGMT)
source: myfinsight.com